Clinical trials: Steroid Refractory
Graft vs Host Disease, Alogenic Hematopoietic Transplant
Rituximab for GVHD
This is a prospective, open-label pilot study in which 4 doses of Rituximab are administered to patients who have developed SR-aGVHD following allogeneic hematopoietic transplant (AHT).
- Trial name
- Rituximab GVHD (NCT00578591)
- Testing
- Rituximab
- Where
- 2 sites in United States
- Sponsor
- Baylor College of Medicine
Graft Versus Host Disease, Unspecified Adult Solid Tumor, Protocol Specific
Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant
RATIONALE: Thalidomide may interfere with the body's ability to recognize transplanted bone marrow cells as foreign and may help treat patients with graft-versus-host disease.
- Conditions
- Graft Versus Host Disease, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00003894
- Testing
- thalidomide
- Where
- 10 sites in United States
- Volunteers
- 36 people
- Sponsor
- Roswell Park Cancer Institute
Graft Versus Host Disease
Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients
In this study the investigators evaluate the outcomes of six steroid-refractory GVHD patients with gastrointestinal signs of GVHD that were treated with teduglutide.
- Trial name
- NCT04290429
- Testing
- Teduglutide
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- University of Freiburg
Asthma
Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma
This is a randomised, double-blind, placebo-controlled, parallel-group, multicenter study of mepolizumab in comparison with placebo in reducing Oral Corticosteroid (OCS) use in subjects with severe refractory asthma.
- Trial name
- NCT01691508
- Testing
- Mepolizumab, OCS (prednisone/prednisolone)
- Where
- 47 sites in United States, Australia and 8 more
- Volunteers
- 135 people
- Sponsor
- GlaxoSmithKline
Thyroid Eye Disease, TED, Graves Ophthalmopathy
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Thyroid Eye Disease (TED), also known as Graves' orbitopathy, is an autoimmune condition that causes inflammation and tissue expansion behind the eyes, leading to bulging eyes (proptosis), double vision, and pain.
- Conditions
- Thyroid Eye Disease, TED, Graves Ophthalmopathy, Graves Orbitopathy
- Trial name
- TOFA-GO (NCT07547930)
- Testing
- Tofacitinib
- Where
- China
- Volunteers
- 8 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Graft vs Host Disease
A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease
This study was been conducted to evaluate the safety, tolerability, and activity of belumosudil (formerly known as KD025) in adult participants with chronic graft versus host disease (cGVHD).
- Trial name
- NCT02841995
- Testing
- Belumosudil (KD025)
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- Kadmon, a Sanofi Company
Acute Graft vs Host Disease
Jaktinib for Steroid-Refractory Acute Graft-Versus-Host Disease
Graft-versus-host disease (GVHD) is a common severe complication and a primary cause of mortality following allogeneic hematopoietic stem cell transplantation (allo-HSCT).Previous studies have demonstrated that the JAK/STAT…
- Trial name
- NCT07885228
- Testing
- Jaktinib
- Where
- 24 sites in China
- Volunteers
- 49 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Graft Versus Host Disease
High-Dose Cyclophosphamide for Steroid Refractory GVHD
RATIONALE: High-dose cyclophosphamide may be an effective treatment for acute graft-versus-host disease that did not respond to steroid therapy.
- Trial name
- NCT00492921
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colitis, Ulcerative
Fecal Microbiota Alterations in Steroid Refractory Active Colitis Ulcerosa
Alterations in the intestinal microbiota have been associated to disease pathogenesis in ulcerative colitis. Refractory disease to standard medical therapy as corticosteroids often leads to an unfavourable course in patients…
- Trial name
- NCT03460847
- Testing
- Steroids
- Where
- Austria
- Volunteers
- 114 people
- Sponsor
- Medical University of Graz
Graft vs Host Disease
Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease
The purpose of this study is to determine if rituximab is a safe and effective therapy for steroid-refractory chronic graft versus host disease (GVHD).
- Trial name
- NCT00136396
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Immune Thrombocytopenic Purpura (ITP)
Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease characterized by antibody-mediated platelet destruction. The complex pathogenesis of ITP with multiple challenges to immune system in terms of genetic…
- Trial name
- NCT02877212
- Testing
- Eltrombopag
- Where
- Pakistan
- Volunteers
- 75 people
- Sponsor
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Graft vs Host Disease
A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease
To determine if subjects with steroid refractory cGVHD can tolerate imatinib mesylate and whether their cGVHD responds to imatinib mesylate.
- Trial name
- NCT00760981
- Testing
- Imatinib
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- David Miklos
Steroid Refractory GVHD
ECP Combination Study
Extracorporeal photopheresis (ECP) offers an alternative to standard immunosuppression and shows an immunomodulatory rather than an immunosuppressive effect, which is associated with less toxicities and side effects.
- Trial name
- NCT05052385
- Testing
- Ruxolitinib, Extracorporeal photopheresis, Ibrutinib
- Where
- 38 sites in Belgium, Denmark and 12 more
- Volunteers
- 319 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Uveitis Related Cystoid Macular Edema, Steroid-induced Glaucoma - Borderline
The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema
Anti-vascular endothelial growth factor (VEGF) treatments show great promise in the treatment of a variety of retinal diseases. This study addresses a condition which affects a large number of our patients in whom the…
- Trial name
- NCT01564108
- Testing
- Ranibizumab
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Graft vs Host Disease
Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD
The purpose of this study is to see whether serious graft versus host disease which is not well controlled with steroid treatment can be controlled with therapy with both daclizumab and infliximab.
- Trial name
- NCT00574470
- Testing
- daclizumab, infliximab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Iowa
cGVHD, HSCT
Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).
This study aims to evaluate the safety and efficacy of Gecacitinib in patients with steroid-refractory/dependent active chronic graft versus host disease (cGVHD).
- Trial name
- CONTINUUM-GVHD (NCT07476872)
- Testing
- Gecacitinib
- Volunteers
- 33 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Graft Versus Host Disease
In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus
In this study the investigators are proposing to treat patients with steroid-refractory Graft-versus-host Disease (GVHD) stabilization using IL-2 and azacitidine
- Trial name
- T-REG (NCT01453140)
- Testing
- Cyclophosphamide and Sirolimus, Low dose IL-2 with Cytoxan + Sirolimus, Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Hackensack Meridian Health
Steroid-Refractory Acute Graft Versus Host Disease
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
This is an open-label, randomized, Phase 3, multicenter trial, which has been designed to compare the efficacy and safety of T-Guard to ruxolitinib in patients with Grade III or IV Steroid-Refractory acute Graft-Versus-Host…
- Trial name
- 2002 (NCT04934670)
- Testing
- T-Guard, Ruxolitinib
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 12 people
- Sponsor
- Xenikos
Graft vs Host Disease
Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease
To study the effectiveness of an immunosuppressive drug sirolimus, in the treatment of chronic graft versus host disease in combination with prednisone.
- Trial name
- NCT00388362
- Testing
- Sirolimus, Prednisone
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Stanford University
Chronic Graft vs Host Disease
Donor Regulatory T-cells for cGVHD in Patients Who do Not Obtain Complete Remission With Ruxolitinib
Phase II clinical trial to assess the efficacy of donor regulatory enriched T cells in steroid-refractory chronic graft versus host disease patients who did not obtain complete remission under treatment with ruxolitinib
- Trial name
- Treg4GVHD (NCT05095649)
- Testing
- Regulatory T-cell enriched infusion
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla